https://www.stabilitystudies.in Pharma Stability: Insights, Guidelines, and Expertise Wed, 05 Nov 2025 05:09:55 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://www.stabilitystudies.in/synchronize-drug-device-stability-with-functional-device-performance-testing/ Wed, 05 Nov 2025 05:09:55 +0000 https://www.stabilitystudies.in/?p=4208 Read More “Synchronize Drug-Device Stability with Functional Device Performance Testing” »

]]> Understanding the Tip:

Why device functionality matters in combination product stability:

Drug-device combination products—such as prefilled syringes, inhalers, autoinjectors, and nasal sprays—must not only maintain chemical stability but also deliver accurate, reproducible doses throughout their lifecycle. Functional components like actuators, plungers, and valves may degrade, stiffen, or fail under long-term storage. Without integrated device performance checks within the stability protocol, a product may chemically remain stable but mechanically become unusable or unsafe.

Risks of excluding device checks from stability testing:

If device function is not monitored:

• Delivery failures (e.g., dose misfire, blockage) may go undetected
• User interface components may degrade and impair usability
• Regulatory agencies may challenge product reliability
• Post-market complaints and recalls may increase

Functional stability is as important as chemical stability for patient-centric combination products.

Regulatory and Technical Context:

Guidance from ICH, WHO, and FDA on combination product performance:

ICH Q1A(R2) and WHO TRS 1010 require that all properties affecting product quality and performance be evaluated throughout shelf life. The FDA’s Combination Product Quality Guidance further mandates that both constituent parts—drug and device—must retain functionality. CTD Module 3.2.P.8.3 and 3.2.R should include device functionality data to support approval.

What auditors and reviewers may request:

Inspectors often ask for:

• Device function test protocols and results at each stability time point
• Actuation force, spray pattern, dose accuracy, or priming studies
• Evidence of interaction between drug formulation and device material (e.g., plunger glide, silicone migration)

Absence of these data may lead to conditional approvals or post-approval testing obligations.

Best Practices and Implementation:

Design an integrated drug-device stability protocol:

Include:

• Chemical testing (e.g., assay, impurity, pH)
• Physical inspection (e.g., appearance, leakage)
• Device testing (e.g., dose delivery, actuator functionality, user interface integrity)

Test entire drug-device units—not just drug content—under ICH stability conditions (long-term, intermediate, accelerated).

Use validated functional test methods tailored to the device type:

Define device-specific metrics such as:

• Spray angle and plume geometry for nasal/oral sprays
• Injection force and glide testing for autoinjectors
• Dose reproducibility and priming effort for inhalers

Conduct tests at relevant stability intervals (e.g., 0M, 3M, 6M, 9M, 12M) and under stress conditions if required.

Document device performance trends and correlate with product usability:

Summarize:

• Functional pass/fail rates across time points
• Correlation between device drift and environmental exposure (e.g., cold chain, humidity)
• Any user feedback simulations from human factors testing

Reference all findings in CTD and maintain device-lot traceability throughout the study.

Aligning drug-device combination stability protocols with periodic device functionality testing ensures that the product is not only chemically intact but also mechanically reliable—delivering the right dose, in the right way, every time until expiry.

]]> https://www.stabilitystudies.in/include-all-stability-dimensions-chemical-physical-and-functional-parameters/ Sun, 26 Oct 2025 11:10:35 +0000 https://www.stabilitystudies.in/?p=4198 Read More “Include All Stability Dimensions: Chemical, Physical, and Functional Parameters” »

]]> Understanding the Tip:

Why stability studies must be multidimensional:

Stability testing must go beyond chemical assay and impurities. A true stability program must evaluate three critical aspects of product quality: chemical (potency and degradation), physical (appearance, viscosity, dissolution), and functional (performance-specific parameters such as drug release, reconstitution, or device actuation). Each parameter contributes to ensuring the product maintains its safety, efficacy, and usability throughout its labeled shelf life.

Consequences of focusing solely on chemical testing:

Without a holistic approach:

• Products may meet assay specs but fail in functional delivery (e.g., inhalers, injectables)
• Physical issues such as sedimentation, color change, or viscosity drift may go undetected
• Risk of patient dissatisfaction or therapeutic failure increases
• Regulatory reviewers may question data completeness and require protocol amendment

Comprehensive stability ensures the product performs as intended under all conditions.

Regulatory and Technical Context:

ICH and WHO guidance on broad-spectrum testing:

ICH Q1A(R2) requires monitoring attributes that are “susceptible to change during storage.” WHO TRS 1010 reinforces this, stating that stability testing should evaluate all properties likely to influence quality. CTD Modules 3.2.P.5.6 (Justification of Specifications) and 3.2.P.8.3 (Stability Data Summary) must include these broader assessments—especially for complex formulations or delivery systems.

Audit readiness and dossier expectations:

Inspectors and reviewers often seek evidence that:

• Functional performance was verified at each time point (e.g., spray pattern, syringe force)
• Physical appearance and viscosity trends were tracked over time
• Stability data reflects real-world handling and use (e.g., after reconstitution)

Lack of physical or functional data can lead to supplemental queries, shelf-life limitations, or even product recalls.

Best Practices and Implementation:

Define all three categories in the stability protocol:

Include:

• Chemical: Assay, impurities, pH, and preservative content
• Physical: Appearance, color, viscosity, re-dispersibility, phase separation
• Functional: Delivery performance, actuation force, reconstitution time, drug release profiles

Set meaningful acceptance criteria for each, tailored to the product’s dosage form and usage profile.

Align testing frequency and conditions to stability risks:

Ensure all three parameter sets are tested at each time point (0M, 3M, 6M, etc.) under:

• Long-term (e.g., 25°C/60% RH)
• Accelerated (e.g., 40°C/75% RH)
• Intermediate and special conditions if required (e.g., photostability, freeze-thaw)

Track all trends using validated methods and qualified instrumentation.

Document findings and link to shelf-life decisions:

Use a consolidated stability summary format that:

• Integrates chemical, physical, and functional observations
• Supports justification of expiry dating period
• Demonstrates performance across full product lifecycle

Reference these findings in QA review, submission documents, and lifecycle management plans.

Including chemical, physical, and functional parameters in your stability study transforms a basic test plan into a comprehensive quality evaluation—strengthening regulatory compliance, ensuring product success, and reinforcing patient trust.

]]>